Abstract
Sir, In their editorial ‘Zidovudine monotherapy in pregnancy: is it state of the art?’ Katzenstein and Gerstoft [1] suggest that the inclusion of zidovudine monotherapy (ZDVm) in the latest version of the British HIV Association (BHIVA) guidelines [2] for the management of HIV in pregnancy might be ‘a remnant from an earlier recommendation that has not been formally disqualified by clinical studies’. We would suggest that there is a more positive case and here consider their four aims of antiretroviral (ARV) therapy in pregnancy in this light.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
